Sarepta Therapeutics Announces Pricing Of $100.7 Million Public Offering Of Common Stock

Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has priced an underwritten public offering of an aggregate of 2,650,000 shares of its common stock at a price to the public of $38.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 397,500 shares of common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the aggregate net proceeds from the offering will be approximately $94.5 million, after deducting the underwriting discount and estimated offering expenses payable by Sarepta, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about April 29, 2014, subject to customary closing conditions.

BofA Merrill Lynch, Morgan Stanley and Deutsche Bank Securities are acting as joint book-running managers for the offering. In addition, Baird, William Blair and Canaccord Genuity are acting as co-managers for the offering.

Sarepta intends to use the net proceeds from the offering for business development, manufacturing, the continued development of eteplirsen and other product candidates and other general corporate purposes.

The shares are being offered by Sarepta pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s web site at Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at; or Morgan Stanley at 180 Varick Street, Second Floor, New York, New York 10014, Attention: Prospectus Department.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Sarepta, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work